GLP-1 Receptor Agonist Services

GLP-1 Significance in Research and Therapeutics

Due to its beneficial effects on glucose control and potential for weight loss, GLP-1 and its analogs have become a focus for the development of therapies for type 2 diabetes and obesity.

Read More »

GLP-1 receptor agonists, which are synthetic versions of the hormone, mimic the action of natural GLP-1 and have been approved for the treatment of type 2 diabetes. These medications not only help to improve glycemic control but also have been shown to have cardiovascular benefits in some patients.
Research continues to explore the broader therapeutic potential of GLP-1, including its effects on the cardiovascular system, brain function, and its potential role in the treatment of conditions beyond type 2 diabetes, such as Parkinson's disease and Alzheimer's disease. The understanding of GLP-1 and its physiological functions has significantly advanced our approach to managing conditions related to glucose metabolism and obesity.

Advancements in GLP-1 Therapy: Specialized Peptide Solutions

In the advancement of GLP-1 therapies, researchers employ fatty acid modification and Fc fusion protein techniques to enhance the effectiveness of GLP-1 receptor agonists. Recognizing the limitations of natural GLP-1's brief half-life, GenScript specializes in providing high-quality peptides that are essential for these sophisticated modifications.

To date, more than a dozen GLP-1 drugs have been launched globally. To better accelerate your GLP-1 new drug research and development, GenScript is now offering GLP-1 Receptor Agonist Services.

Read More about GenScript GLP-1 capability in the GenScript successful case section.

Highlights

One-Stop Service

From early drug screening, process development to cGMP production

Diversified Solutions

Robust modification techniques including advanced conjugation services with small-molecule drugs

Regulatory Compliance CMC Service

Streamlining GLP-1 analogs development and registration with comprehensive CMC services

How GenScript can support your GLP-1RA Drug Discovery

From Drug Discovery to Support for Clinical Trials

GenScript Successful Case

• Successful Synthesis & Delivery of GLP-1 RA peptide

  Report Gene Assay in HEK293/LUC/INSR Cells

  

  	GenScript	Commercial Product
  EC50	9.34e-007	9.904e-007

  As shown in the figure above, the bioactivity test results for the two samples are consistent, both effectively inducing the expression of Luciferase protein in HEK293/Luc/INSR cells. This indicates that the GLP-1RA synthesized by GenScript is of stable quality and exhibits bioactivity comparable to that of commercial products.

  Detection of GLP-1 RA peptide purity
  by HPLC confirms high purity

  

  Molecular weight of the GLP-1 RA peptide has been
  accurately confirmed through mass spectrometry detection

  

  The purity of the GLP-1 RA peptide is consistent across
  multiple synthesis batches

  

  GenScript successfully delivered 30 g of GLP-1 RA peptide (95% purity) within 45 days

• Advanced GLP-1 RA Peptide & Linker Production

  GenScript offers specialized expertise in peptide synthesis, with the capacity to support the development of cutting-edge hypoglycemic drugs targeting multiple receptors such as GLP-1 RA peptide including GLP-1 activating peptide of novel drug AMG133.

  AMG133 represents a breakthrough conjugate treatment for type 2 diabetes, created to enhance patient convenience with a once-monthly dosing regimen. This innovative treatment synergistically combines a fully human monoclonal antibody, aimed at the GIP receptor (GIPR) — a target for blood sugar control — with a GLP-1 agonist peptide analog, which is a molecule designed to stimulate insulin release [Véniant, M.M. et al. Nat Metab (2024)].

  

  Adapted from Véniant, M.M. et al. Nat Metab (2024) with modification.

  At GenScript, we have the capabilities to synthesize complex peptides and linkers, which are crucial components in groundbreaking drugs like AMG133. Our advanced solutions are contributing to a revolutionary approach in the development of hypoglycemic drugs, particularly in the management of diabetes and support in weight loss.

GenScript Expands Peptide Production Capabilities to Include Neoantigen Peptides and APIs!